Functional activation of mutant human insulin receptor by monoclonal antibody

Lancet

Volumn 347, Issue 9015, 1996, Pages 1586-1590

  Krook, Anna ^a,b   Soos, Maria A ^a,b   Kumar, Sudhesh ^c   Siddle, Kenneth ^b   O'Rahilly, Stephen ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CELL SURFACE RECEPTOR; GLYCOGEN; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; MUTANT PROTEIN;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CASE REPORT; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; FEMALE; GLYCOGEN SYNTHESIS; HUMAN; HYPERGLYCEMIA; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RABSON MENDENHALL SYNDROME;

EID: 0029897480     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91076-4     Document Type: Article

References (22)

1. Pearce SHS, Trump D. G-protein-coupled receptors in endocrine disease. Q J Med 1995; 88: 3-8.
2. Kopp P, van Sande J, Parma J, et al. Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995; 332: 150-54.
3. Utiger RD. Thyrotropin-receptor mutations and thyroid dysfunction. N Engl J Med 1995; 332: 183-85.
4. Clark AJL, McLoughlin L, Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 1993; 341: 461-62.
5. Rosenthal W, Antaramian A, Gilbert S, Birnbaurner M. Nephrogenic diabetes insipidus: a V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem 1993; 268: 13030-33.
6. O'Rahilly S, Moller DE. Mutant insulin receptors in syndromes of insulin resistance. Clin Endocrinol 1992; 36: 121-32.
7. Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696-705.
8. Zenobi PD, Holzmann P, Glatz Y, Riesen WF, Froesch ER. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia 1993; 36: 465-69.
9. Kolaczynski JW, Caro JF. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann Intern Med 1994; 120: 47-55.
10. Krook A, Kumar S, Lang I, Boulton AJM, Wass JAH, O'Rahilly S. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes 1994; 43: 357-68.
11. Roach P, Zick Y, Formisano P, Accili D, Taylor SI, Gorden P. A novel human insulin receptor mutation uniquely inhibits insulin binding without impairing post translational processing. Diabetes 1994; 43: 1096-102.
12. DeMeyts P. The structural basis of insulin and insulin-like growth factor-1 receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 1994; 37 (suppl 2): S135-48.
13. Taylor R, Soos MA, Wells A, Argyraki M, Siddle K. Insulin-like and insulin-inhibitory effects of monoclonal antibodies for different epitopes on the human insulin receptor. Biochem J 1987; 242: 123-29.
14. LeBrun C, Baron V, Kaliman P, et al. Antibodies to the extracellular domain restore the hormone insensitive kinase and conformation of the mutant insulin receptor valine 382. J Biol Chem 1993; 268: 11272-77.
15. Ebina Y, Araki E, Taira M, et al. Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin and antibody-stimulated glucose uptake and receptor kinase activity. Proc Natl Acad Sci USA 1987; 84: 704-08.
16. 'tHart LM, Lindhold D, Van der Zon GCM, et al. An insulin receptor mutant (Asp707Ala), involved in leprechaunism, is processed and transported to the cell surface but unable to bind insulin. J Biol Chem (in press).
17. Moller DE, O'Rahilly S. Syndromes of severe insulin resistance. In: Moller DE, ed. Insulin resistance. New York: John Wiley and Sons Ltd, 1993: 49-81.
18. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326: 1153-57.
19. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patient with lymphoid malignancies: effects of antibody isotype. Blood 1989; 73: 1431-39.
20. Waldmann H, Cobbold S. The use of monoclonal antibodies to achieve immunological tolerance. Immunol Today 1993; 14: 247-51.
21. Smith RM, Fairchild PJ. Monoclonal antibodies: harnessing the potential. Sci Progr Oxford 1992; 76: 323-43.
22. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993; 14: 243-46.